Clinical endpoints
HER-2
LEFT VENTRICULAR DYSFUNCTION
Only 2 patients met the criteria for CTRCD and both were asymptomatic. Left ventricular dysfunction was detected during the follow-up echocardiogram at 3-month post doxorubicin therapy. Both patients were receiving trastuzumab treatment at the time CTRCD was discovered as they had HER-2 positive status. Cardioprotective treatment with beta-blocker and angiotensin-converting enzyme inhibitor were prescribed. Both patients had an improvement of LVEF to 50% on the follow-up echocardiogram. No patient died during trial follow-up.